Protagonist Therapeutics (PTGX) could be a great long-term investment
What’s up with Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) opened at $16.35, which means the stock is down 0.49% from yesterday’s closing price of 16.28. Today, the company has a high of $16.50 and a low of $15.82. The company has a market cap of $557.85 million with a 52-week high of $24.00 and a 52-week low of $4.53.
What about the future for Protagonist Therapeutics?
The high forecast for Protagonist Therapeutics is $16.00 while the low is $12.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Protagonist Therapeutics has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information PTGX seems to be a safe buy.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.